LEAP-NK Trademark

Trademark Overview


On Friday, May 5, 2023, a trademark application was filed for LEAP-NK with the United States Patent and Trademark Office. The USPTO has given the LEAP-NK trademark a serial number of 97923040. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Saturday, February 8, 2025. This trademark is owned by BioCentriq, Inc.. The LEAP-NK trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacturing of biopharmaceutical preparations for cell and gene therapy and stem cell therapy

Testing, research, and development of biopharmaceutical preparations for cell and gene therapy and stem cell therapy; Scientific services, namely, testing, scientific research and development in the field of processes for cell and gene therapy and stem cell therapy; stem cell research services and clinical research in the field of gene therapy; consulting services in the fields of biopharmaceutical research and development and genetic science
leap-nk

General Information


Serial Number97923040
Word MarkLEAP-NK
Filing DateFriday, May 5, 2023
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateSaturday, February 8, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesCustom manufacturing of biopharmaceutical preparations for cell and gene therapy and stem cell therapy
Pseudo MarkLEAP NK
Goods and ServicesTesting, research, and development of biopharmaceutical preparations for cell and gene therapy and stem cell therapy; Scientific services, namely, testing, scientific research and development in the field of processes for cell and gene therapy and stem cell therapy; stem cell research services and clinical research in the field of gene therapy; consulting services in the fields of biopharmaceutical research and development and genetic science

Classification Information


International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateThursday, August 15, 2024
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, June 5, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBioCentriq, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNewark, NJ 07103

Trademark Events


Event DateEvent Description
Tuesday, May 9, 2023NEW APPLICATION ENTERED
Monday, June 5, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 24, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, July 24, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, July 24, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 31, 2024ASSIGNED TO EXAMINER
Thursday, February 15, 2024NON-FINAL ACTION WRITTEN
Thursday, February 15, 2024NON-FINAL ACTION E-MAILED
Thursday, February 15, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 15, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, May 15, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, August 15, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 15, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 16, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 18, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, October 18, 2024FINAL REFUSAL WRITTEN
Friday, October 18, 2024FINAL REFUSAL E-MAILED
Saturday, February 8, 2025ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Saturday, February 8, 2025ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE